Article Text

other Versions

PDF
Use of infliximab in juvenile onset rheumatological disease associated refractory uveitis: Efficacy in joint and ocular disease
  1. Srilakshmi M Sharma (s_m_sharma{at}yahoo.com)
  1. University Department of Ophthalmology, Bristol Eye Hospital, United Kingdom
    1. Athimalaipet V Ramanan (athimalaipet.ramanan{at}nbt.nhs.uk)
    1. North Bristol NHS Trust & Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
      1. Philip Riley (philip.riley{at}nbt.nhs.uk)
      1. North Bristol NHS Trust & Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
        1. Andrew D Dick (a.dick{at}bristol.ac.uk)
        1. University Department of Ophthalmology, Bristol Eye Hospital, United Kingdom

          Abstract

          There is an identified disparity between the efficacy of TNF ( tumor necrosis factor) inhibition in the treatment of uveitis in paediatric onset inflammatory arthritis and that of joint disease (1,2,3,4,5).

          We retrospectively reviewed the case notes of 6 patients with aggressive, refractory joint and ocular paediatric- onset disease treated with infliximab in a multi- disciplinary clinic. Our report utilizes the Standardised Uveitis Nomenclature (SUN) grading system (6) for uveitis and steroid dose as an outcome measure. All patients received infliximab infusions at weeks 0, 2, 6 and 8 weekly.

          • TNF-alpha
          • infliximab
          • juvenile Inflammatory Arthritis
          • juvenile onset sarcoidosis
          • uveitis

          Statistics from Altmetric.com

          Request permissions

          If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.